IRTC on XNAS, Health Care, iRhythm Holdings, Inc., job postings
Measures activity, not value. Not investment advice.
Insiders bought $764K in 90 days while shares fell 44% over 12 months.
BadShort interest 9.7% of shares, up 5.5% between reports two weeks apart
BadLost $38.6M over 12 months on $854M revenue
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $221.6M, net loss $29.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $224.2M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$221.6M
-$29.9M
30 Jun 2026
$224.2M
-$381K
31 Mar 2026
$199.4M
-$13.9M
31 Dec 2025
$208.9M
$5.6M
30 Sep 2025
$192.9M
-$5.2M
30 Jun 2025
$186.7M
-$14.2M
31 Mar 2025
$158.7M
-$30.7M
31 Dec 2024
$164.3M
-$1.3M
30 Sep 2024
$147.5M
-$46.2M
30 Jun 2024
$148.0M
-$20.1M
31 Mar 2024
$131.9M
-$45.7M
31 Dec 2023
$132.5M
-$38.7M
30 Sep 2023
$124.6M
-$27.1M
30 Jun 2023
$124.1M
-$18.5M
31 Mar 2023
$111.4M
-$39.1M
31 Dec 2022
$112.6M
-$20.2M
30 Sep 2022
$103.9M
-$21.5M
30 Jun 2022
$102.1M
-$23.9M
31 Mar 2022
$92.4M
-$50.6M
31 Dec 2021
$81.8M
-$32.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$854.0M
$702.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+22%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$38.6M
-$51.5M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.16
-$1.61
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
72.3%
70.4%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-5.7%
-9.1%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-4.5%
-7.3%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-25.8%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$7.4M
$32.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$560.7M
$565.2M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$651.9M
$648.8M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$91.1M
$83.5M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
3.7
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$5.27
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
3.7
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
3.8
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
18.0
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+15%
$221.6M vs $192.9M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+7.8%
$16.0M vs $14.8M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$670K
bought $764K, sold $94K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+5.3%
316 13F filers vs 300
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
36.1M shares held by 13F filers (30 Sep 2026) of 33.6M outstanding (29 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
9.7%
3.3M shares sold short (30 Oct 2026) of 33.6M outstanding (29 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
6.7
3.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+5.5%
3.1M shares sold short in the report before, 3.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
49%
49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$200K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
27
27 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
9.0×
27 articles in the last 7 days; its usual week has 3.
Unusual now sharp changes in the last 90 days, compared with its own past
New lobbying issue
Price $94.72 on 20 Nov 2026, -44% over 12 months (12-month range $86.06 to $189.25)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $23.7M in the last 12 months (the 12 months before: -$25.7M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 3 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $221.6M in the latest quarter, +15% on a year earlier.Capital spending per quarter. Capital spending $16.0M in the latest quarter, +7.8% on a year earlier.Institutional holders (13F filers). 316 13F filers reported holding it in the latest 13F quarter, +0.6% on a year earlier.Lobbying spend. Lobbying spend: $200K published in the last 12 months, -17% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
In 12 months: 4 director or officer changes, 2 major agreements, 1 auditor change, 1 cybersecurity incident. Results releases and routine reports are left out.
Filed
What happened
Source
13 Nov 2026
Adopted a nonqualified deferred compensation plan effective Jan 1, 2027, letting employees and directors defer salary, bonus and fees
Reported lobbying spend: $50K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Apr 2026
New
Mehlman Consulting, Inc.for Irhythm Technologies, Inc.
Ensuring access to appropriate medical technology for cardiac patients.Health issues, Medicare/Medicaid, VET
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.Medicare/Medicaid
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to the Medicare Physician Fee Schedule. Issues related to Covid 19.; Issues related to artificial intelligence.Medicare/Medicaid, Health issues
Two or more unrelated kinds of records unusual within 30 days
17 Nov 2021confirmed
Confirmed across sources Filings + Financials and Lobbying
iRhythm(IRTC): spent $13.3M on capital projects in the quarter ended 30 Sep 2021, 2.4× the same quarter last year, while it registered for federal lobbying for the first time in our data (Williams And Jensen, Pllc). Two unrelated kinds of activity within 7 days.
Financials: Quarterly capital spending jump, became public on 9 Nov 2021
Lobbying: First lobbying registration, became public on 17 Nov 2021
The quarter ended 30 Sep 2021 against the 8 quarters before it.
this quarterearliernormal: $3.8MSee the evidence (2 changes)
Financials: Quarterly capital spending jump became public on 9 Nov 2021
iRhythm spent $13.3M on capital projects in the quarter ended 30 Sep 2021, 2.4× the same quarter last year.
This period
$13.3M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$3.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+5.3
Same quarter last year
$5.6M
History used
2,100 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $3.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
filed a director or officer change: Adopted a nonqualified deferred compensation plan effective Jan 1, 2027, letting employees and directors defer salary, bonus and fees.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
spent $14.8M on capital projects in the quarter ended 30 Sep 2025, 1.7× the same quarter last year.
Same quarter last year: $8.8M; its normal quarter is $9.3M.
See the evidence
This period
$14.8M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$9.3M
Typical spread (median absolute deviation)
$644K
How far from its usual level
+5.6
Same quarter last year
$8.8M
History used
3,561 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $9.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 64 13F filers open a new position in the quarter ended 30 Jun 2025, 2.8× the same quarter last year.
Same quarter last year: 23; its normal quarter is 28.5.
See the evidence
This period
64 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
28.5
Typical spread (median absolute deviation)
4.5
How far from its usual level
+5.3
Same quarter last year
23
History used
3,103 days
the quarter ended 30 Jun 20258 earlier quartersnormal: 28.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 49 13F filers open a new position in the quarter ended 31 Mar 2025, 1.0× the same quarter last year.
Same quarter last year: 49; its normal quarter is 26.5.
See the evidence
This period
49 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
26.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+6.1
Same quarter last year
49
History used
3,012 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 26.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 40 13F filers open a new position in the quarter ended 30 Sep 2024, 1.3× the same quarter last year.
Same quarter last year: 31; its normal quarter is 25.5.
See the evidence
This period
40 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
25.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.8
Same quarter last year
31
History used
2,830 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 25.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 49 13F filers open a new position in the quarter ended 31 Mar 2024, 1.8× the same quarter last year.
Same quarter last year: 27; its normal quarter is 26.5.
See the evidence
This period
49 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
26.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+6.1
Same quarter last year
27
History used
2,647 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 26.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
spent $10.8M on capital projects in the quarter ended 30 Jun 2022, 1.8× the same quarter last year.
Same quarter last year: $5.9M; its normal quarter is $5.1M.
See the evidence
This period
$10.8M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$5.1M
Typical spread (median absolute deviation)
$856K
How far from its usual level
+4.5
Same quarter last year
$5.9M
History used
2,373 days
the quarter ended 30 Jun 20228 earlier quartersnormal: $5.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.
Not listed: 333 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001388658
Ticker
IRTC
Domain
irhythmtech.com
Employer name
irhythm technologies (1 unverified)
Hq location
CA|SAN FRANCISCO|94103 (1 unverified)
Lobbying client
irhythm technologies
Name
EX-21.1, ex211listofsubsidiaries, ex211listofsubsidiaries.htm, iRhythm Holdings, Inc. and 1 more
DOL H-1B labor condition applications and PERM certifications19 data points9 Mar 2026 to 14 Sep 2026
Federal lobbying disclosures (LDA)7 records, 84 data points1 Jan 2011 to 30 Sep 2026
SEC Form 13F institutional holdings1 record, 360 data points31 Dec 2016 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)162 records23 Sep 2016 to 17 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)925 data points31 Dec 2013 to 29 Oct 2026
SEC Form 4 insider transactions232 records, 592 data points25 Oct 2016 to 19 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026